Drug updated on 3/28/2024
| Dosage Form | Capsule (oral; 10 mg) |
| Drug Class | Complement 5a receptor antagonists |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA] and microscopic polyangiitis [MPA]) in combination with standard therapy including glucocorticoids. TAVNEOS does not eliminate glucocorticoid use.
Summary
- Avacopan (Tavneos) is indicated as an adjunctive treatment for adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis, specifically granulomatosis with polyangiitis [GPA] and microscopic polyangiitis [MPA], in combination with standard therapy including glucocorticoids.
- The document reviewed was a systematic review/meta-analysis, which included one study that discussed the effectiveness of various interventions used to treat renal vasculitis in adults.
- Plasma exchange as an adjunctive therapy significantly reduces the risk of end-stage kidney disease at three months and 12 months according to two studies mentioned within the study.
- Pulse cyclophosphamide results in an increased risk of relapse when compared to continuous oral use but allows for a reduced total dose; this information could be crucial while considering treatment options alongside avacopan (Tavneos).
- Other effective remission induction agents include rituximab and mycophenolate mofetil, whereas azathioprine, methotrexate and leflunomide were found effective as maintenance therapies after initial successful treatment.
- Despite its potential benefits, oral co-trimoxazole did not significantly reduce relapses in granulomatosis with polyangiitis according to the findings from the studies reviewed.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Tavneos (avacopan) Prescribing Information. | 2021 | ChemoCentryx Inc., San Carlos, CA |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Assessment report: Tavneos. | 2022 | EMA |
| Interventions for renal vasculitis in adults. | 2020 | Cochrane Database of Systematic Reviews |